---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-113467"
form_type: "8-K"
ticker: "RAPH"
cik: "0001415397"
company_name: "Raphael Pharmaceutical Inc."
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:41:35.151105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Raphael Pharma reports positive proof-of-concept study of cannabinoid formula in RA

## Summary
- DAS28 score reduced by 19.2%, moving from high to moderate disease activity in 12 patients.
- Participants in remission increased from 0% at baseline to 16.67% at week 8.
- Pain levels dropped from 75% reporting negative result to 50%; morning stiffness from 75% to 41.67%.
- 91.7% of participants would recommend Raphael's Formula to others with RA; 83.3% willing to continue use.
- Blood biomarkers showed no statistically significant changes, but overall symptom management improved.

## SEC filing metadata
- accession: 0001213900-24-113467
- form_type: 8-K
- ticker: RAPH
- cik: 0001415397
- company_name: Raphael Pharmaceutical Inc.
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1415397/000121390024113467/0001213900-24-113467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1415397/000121390024113467/ea0226291-8k_raphael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-113467
- JSON: https://secwatch.observer/filing/0001213900-24-113467.json
- Plain text: https://secwatch.observer/filing/0001213900-24-113467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.